

ongoing trials - trial from [www.clinicaltrials.gov](http://www.clinicaltrials.gov)

## **Ph 1/2 Study Evaluating Safety and Tolerability of Inhaled AP-PA02 in Subjects With Chronic Pseudomonas Aeruginosa Lung Infections and Cystic Fibrosis - Phase 1|Phase 2 - Recruiting**

**Code:** NCT04596319    **Year:** 2020    **Date:** December 22, 2020

**Author:** Armata Pharmaceuticals, Inc.|Cystic Fibrosis Foundation

### **Study design (if review, criteria of inclusion for studies)**

Interventional - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment

### **Participants**

Cystic Fibrosis|Pseudomonas Aeruginosa|Pseudomonas|Lung Infection|Lung Infection Pseudomonal - 18 Years and older (Adult, Older Adult)

### **Interventions**

Biological: AP-PA02|Other: Placebo

### **Outcome measures**

Incidence of Treatment Emergent Adverse Events (Safety and Tolerability) of single and multiple doses of AP-PA02 administered by inhalation|Part 2 (MAD) Only: Explore P. aeruginosa recovery in sputum following multiple doses of AP-PA02 administered by inhalation

<https://ClinicalTrials.gov/show/NCT04596319>

### **Keywords**

AP-PA02; Phage therapy; Anti-bacterial agents; pharmacological\_intervention; Bacterial Infections; Infection; Inhalation OR nebulised; Pseudomonas aeruginosa; Pseudomonas; Respiratory Tract Diseases; Respiratory Tract Infections;